Citations

Clear

4564 citation(s) found for "Yu, Virginia".

MRI-Negative Cushing’s Disease: Subtotal Gland Resection versus Gross Total Resection to Preserve Pituitary Gland Function
Erickson, Dana , Henderson, J. Michael, Palit, Sandhya R. , Shinya, Yuki , Bancos, Irina , Henderson, Justine S., Hong, Sukwoo , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803043 Get It

Machine Learning-Based Model to Predict Long-Term Tumor Control and Additional Interventions following Transsphenoidal Surgery for Acromegaly Patients
Sáez-Alegre, Miguel , Erickson, Dana , Davidge‐Pitts, Caroline , Meyer, Fredric B. , Atkinson, John L. D., Shinya, Yuki , Ghaith, Abdul Karim , Herndon, Justine , Palit, Sandhya R. , Hong, Sukwoo , Morshed, Ramin A. , Bancos, Irina , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803039 Get It

Photon-Counting Detector CT Outperforms MRI in Localizing Cushing’s Disease: An Institutional Cohort Study
Pihneiro-Neto, Carlos D., Peris-Celda, Maria, Erickson, Dana , Michalopoulos, Giorgos D. , Mark, Ian T. , Shinya, Yuki , Palit, Sandhya R. , Bancos, Irina , Peris‐Celda, Maria , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803038 Get It

A Multicenter Comparison of CRH versus DDAVP Stimulation Responses in Inferior Petrosal Sinus Sampling for Cushing’s Disease
Karsy, Michael, Silverstein, Julie , Evans, James J., Collopy, Sarah , Kelly, Dan, Fernandez‐Miranda, Juan C. , Pacione, Donato , Bergsneider, Marvin , Zada, Gabriel , Kshettry, Varun R. , Wu, Kyle C., Benjamin, Carolina , Catalino, Michael P. , Zwagerman, Nathan T. , Little, Andrew S. , Yuen, Kevin Choong Ji, ITorok, Ildiko, Gardner, Paul A. , Karsy, Michael , Karsy, Michael , Kim, Albert Sungsoo , Rennert, Robert C , Couldwell, William T. , Barkhoudarian, Garni , Kim, Won Bae , Chicoine, Michael , Gompel, Jamie J. Van , Mamelak, Adam N. , Yuen, Kevin C.J.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803037 Get It

Ezh2 Shapes T Cell Plasticity to Drive Atherosclerosis
Bonfiglio, Cecilia Assunta , Lacy, Michael , Triantafyllidou, Vasiliki, Farina, Floriana Maria , Janjic, Aleksandar , Nitz, Katrin , Wu, Yuting , Marques, Yonara Freire Soares, Kumkum, Mahadia, Röß, Katja, Venkatasubramani, Anuroop Venkateswaran , Weber, Christian , Santovito, Donato , Joppich, Markus , Kumkum, Mahadia , Venkatasubramani, Anuroop Venkateswaran , Maegdefessel, Lars , de Winther, Menno P J , Weber, Christian , Santovito, Donato , Lutgens, Esther , Atzler, Dorothee , Bonfiglio, Cecilia A , Janjic, Aleksandar , Nitz, Katrin , Bazioti, Venetia , Avcilar-Kücükgöze, Irem , Röß, Katja, Imhof, Axel , Enard, Wolfgang , Winther, Menno P.J. de , Lutgens, Esther , Atzler, Dorothee

Mayo Clinic

Circulation | February 7, 2025 | Volume: 151 | Issue: 19 | Pages: 1391-1408

10.1161/circulationaha.124.072384 | PMID 39917842 Get It

BACKGROUND: The activation and polarization of T cells play a crucial role in atherosclerosis and dictate athero-inflammation. The epigenetic enzyme EZH2 (enhancer of zeste homolog 2) mediates the H3K27me3 (trimethylation of histone H3 lysine 27) and is pivotal in controlling T cell responses. METHODS: To detail the role of T cell EZH2 in atherosclerosis, we used human carotid endarterectomy specimens to reveal plaque expression and geography of EZH2. Atherosclerosis-prone Apoe (apolipoprotein E)–deficient mice with CD (cluster of differentiation) 4 + or CD8 + T cell–specific Ezh2 deletion (Ezh2 cd4 -knockout [KO], Ezh2 cd8 -KO) were analyzed to unravel the role of T cell Ezh2 in atherosclerosis and T cell–associated immune status. RESULTS: EZH2 expression is elevated in advanced human atherosclerotic plaques and primarily expressed in the T cell nucleus, suggesting the importance of canonical EZH2 function in atherosclerosis. Ezh2 cd4 -KO, but not Ezh2 cd8 -KO, mice showed reduced atherosclerosis with fewer advanced plaques, which contained less collagen and macrophages, indicating that Ezh2 in CD4 + T cells drives atherosclerosis. In-depth analysis of CD4 + T cells of Ezh2 cd4 -KO mice revealed that absence of Ezh2 results in a type 2 immune response with increased Il-4 (interleukin 4) gene and protein expression in the aorta and lymphoid organs. In vitro, Ezh2 -deficient T cells polarized macrophages toward an anti-inflammatory phenotype. Single-cell RNA-sequencing of splenic T cells revealed that Ezh2 deficiency reduced naive, Ccl5 + (C-C motif chemokine ligand 5) and regulatory T cell populations and increased the frequencies of memory T cells and invariant natural killer T (iNKT) cells. Flow cytometric analysis identified a shift toward Th2 (type 2 T helper) effector CD4 + T cells in Ezh2 cd4 -KO mice and confirmed a profound increase in splenic iNKT cells with increased expression of Plzf (promyelocytic leukemia zinc finger), which is the characteristic marker of the iNKT2 subset. Likewise, Zbtb16 ([zinc finger and BTB domain containing 16], the Plzf-encoding gene) transcripts were elevated in the aorta of Ezh2 cd4 -KO mice, suggesting an accumulation of iNKT2 cells in the plaque. H3K27me3–chromatin immunoprecipitation followed by quantitative polymerase chain reaction showed that T cell–Ezh2 regulates the transcription of the Il-4 and Zbtb16 genes. CONCLUSIONS: Our study uncovers the importance of T cell EZH2 in human and mouse atherosclerosis. Inhibition of Ezh2 in CD4 + T cells drives type 2 immune responses, resulting in an accumulation of iNKT2 and Th2 cells, memory T cells and anti-inflammatory macrophages that limit the progression of atherosclerosis.
Efficacy and safety of preoperative embolization in surgical treatment of brain arteriovenous malformations: a multicentre study with propensity score matching
Salim, Hamza , Hamdan, Dawoud, Adeeb, Nimer , Aslan, Assala , Musmar, Basel , Ogilvy, Christopher S. , Dmytriw, Adam A. , Ataoglu, Cagdas , Erginoğlu, Ufuk , Naamani, Kareem El, Sheehan, Jason P. , Ironside, Natasha , Gummadi, Sanjeev, Keleş, Abdullah , Muram, Sandeep , Sconzo, Daniel , Rezai, Arwin, Alwakaa, Omar , Sen, Rajeev , Başkaya, Mustafa K. , Tjoumakaris, Stavropoula , Atallah, Elias , Riina, Howard A. , Abushehab, Abdallah, Swaid, Christian, Burkhardt, Jan‐Karl , Starke, Robert M., Altschul, David , Haranhalli, Neil , McAvoy, Malia , Abla, Adib A. , Stapleton, Christopher J. , Koch, Matthew J. , Srinivasan, Visish M. , Cochran, Joseph, Pukenas, Bryan , Smith, Edward R. , Moehlenbruch, Markus, Alaraj, Ali , Patel, Aman B. , Yedavalli, Vivek , Cuellar, Hugo H, Lawton, Michael T. , Guthikonda, Bharat , Aslan, Assala , Musmar, Basel , Ogilvy, Christopher S , Dmytriw, Adam A , Essibayi, Muhammed Amir , Alwakaa, Omar , Griessenauer, Christoph J , Jabbour, Pascal , Altschul, David J , Koch, Matthew J , Chen, Peng R , Orbach, Darren B , Alaraj, Ali , Yedavalli, Vivek S , Abla, Adib , Salim, Hamza , Keles, Abdullah , Erginoglu, Ufuk , Smith, Edward , Hamdan, Dawoud , Kandregula, Sandeep , Abdelsalam, Ahmed , Kondziolka, Douglas , Naamani, Kareem El , Kumbhare, Deepak , Essibayi, Muhammed Amir , Tos, Salem M , Rezai, Arwin, Pöppe, Johannes , Sen, Rajeev D, Griessenauer, Christoph J. , Jabbour, Pascal , Sekhar, Laligam N. , Levitt, Michael R. , Blackburn, Spiros , Choudhri, Omar , Orbach, Darren B. , Mosimann, Pascal J , Aziz‐Sultan, Mohammad Ali , Wintermark, Max , Savardekar, Amey Rajan , Morcos, Jacques J.

Mayo Clinic

Journal of Neurology, Neurosurgery & Psychiatry | February 6, 2025 | Volume: 96 | Issue: 8 | Pages: 766-774

10.1136/jnnp-2024-334974 | PMID 39915091 Get It

Background Brain arteriovenous malformations (AVMs) are abnormal connections between feeding arteries and draining veins, associated with significant risks of haemorrhage, seizures and other neurological deficits. Preoperative embolization is commonly used as an adjunct to microsurgical resection, with the aim of reducing intraoperative complications and improving outcomes. However, the efficacy and safety of this approach remain controversial. Methods This study is a subanalysis of the Multicenter International Study for Treatment of Brain AVMs consortium. We retrospectively analysed 486 patients with brain AVMs treated with microsurgical resection between January 2010 and December 2023. Patients were divided into two groups: those who underwent microsurgery alone (n=245) and those who received preoperative embolization, followed by microsurgery (n=241). Propensity score matching was employed, resulting in 288 matched patients (144 in each group). The primary outcomes were rates of complete AVM obliteration and functional outcomes (measured by the modified Rankin Scale (mRS)). Secondary outcomes included complication rates, mortality, hospital length of stay and postsurgical rupture. Results After matching, the complete obliteration rate was 97% with no significant difference between the microsurgery-only group and the preoperative embolization group (p=0.12). The proportion of patients with an mRS score of 0–2 at the last follow-up was similar in both groups (83% vs 84%; p=0.67). The median hospital stay was significantly longer for the embolisation group (9 days vs 7 days; p=0.017). Complication rates (24% vs 22%; p=0.57) and mortality rates (4.9% vs 2.1%; p=0.20) were comparable between the two groups. No significant differences were observed in postsurgical rupture, recurrence or retreatment rates. Conclusions In this large multicentre study, preoperative embolization did not significantly improve AVM obliteration rates, functional outcomes or reduce complications compared with microsurgery alone.
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis
Wood, Cameron , Lyniv, Liliana, Isaacs, James M, Kaufman, Jacob M., Oduah, Eziafa , Clarke, Jeff, Crawford, Jeffrey, Stinchcombe, Thomas E. , Tong, Betty , Wigle, Dennis A. , Dragnev, Konstantin H. , Antonia, Scott , Ready, Neal , Wigle, Dennis, Ready, Neal , Wood, Cameron , Isaacs, James , Wang, Xiaofei , Gu, Lin, Weinhold, Kent J.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | February 4, 2025 | Volume: 13 | Issue: 2 | Pages: e010395

10.1136/jitc-2024-010395 | PMID 39904561 Get It

Background Our study was designed to determine the safety, efficacy, and immunological effects of perioperative pembrolizumab in early-stage NSCLC. Methods This is a single-arm phase II study of perioperative pembrolizumab in patients with untreated, clinical stage IB to IIIA NSCLC. Patients received two doses of 200 mg pembrolizumab, surgery, standard adjuvant chemotherapy, followed by four doses adjuvant pembrolizumab. The primary objective of this study was to determine surgical feasibility rate, and secondary objectives are pathological response rate, treatment adverse events, efficacy data, and exploratory analysis of biomarkers. Results 30 patients initiated perioperative pembrolizumab, and 25 completed tumor resection. At median follow-up of 59 months after surgical resection, seven patients had disease progression, while six had died representing. A 5-year progression-free survival (PFS) from time of surgery was 72.0% (56.4%–91.9%) and overall survival (OS) from time of surgery was 75.8% (60.7%–94.7%). Major pathological response (MPR) was found in seven tumors (28%) including two complete responses (4%). Across all treated patients, four receiving neoadjuvant and four receiving adjuvant pembrolizumab experienced treatment-related adverse events of grade 3 or higher with no grade 5 events. Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) levels increased across our patient cohort over time from baseline until postsurgery and remained elevated at the end of treatment. There was a significant difference between mean plasma PCSK9 levels for patients with MPR versus all other patients on study when checked postoperatively. Conclusions Perioperative pembrolizumab was safe and effective with promising MPR rate, PFS, and OS.
Developing innovative teaching strategies for pain medicine rotations tailored to Generation Z
Banik, Ratan K. , Sandozi, Heba , Bhullar, Sona, Wang, Eric J. , Chai, Thomas , Cheng, Jianguo , Hagedorn, Jonathan M. , Wahezi, Sayed , Kohan, Lynn , Akhtaruzzaman, AKM , Ibrahim, Mohab , Mendelson, Andrew , Hussain, Nasir , Wang, Eric , Hagedorn, Jonathan M , Kohan, Lynn R , Mendelson, Andrew M , Hussain, Nasir , Banik, Ratan K , Bhullar, Sona, Shaparin, Naum , Singh, Ambrish

Mayo Clinic

Regional Anesthesia & Pain Medicine | February 3, 2025 | Volume: No volume available | Issue: No issue available | Pages: rapm-2024-106297

10.1136/rapm-2024-106297 | PMID 39900453 Get It

Impact of Diagnosis to Ablation Time on Recurrence of Atrial Fibrillation and Clinical Outcomes After Catheter Ablation: A Systematic Review and Meta-Analysis With Reconstructed Time-to-Event Data
Amin, Ahmed Mazen , Elbenawi, Hossam , Khan, Ubaid , Almaadawy, Omar , Turkmani, Mustafa , Abdelmottaleb, Wael , Essa, Mohammed , Abuelazm, Mohamed , Abdelazeem, Basel , Asad, Zain Ul Abideen , Deshmukh, Abhishek , Link, Mark S. , DeSimone, Christopher V , Abdelazeem, Basel , Asad, Zain Ul Abideen , Turkmani, Mustafa , Abuelazm, Mohamed , DeSimone, Christopher V.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | February 3, 2025 | Volume: 18 | Issue: 2 | Pages: No page available

10.1161/circep.124.013261 | PMID 39895523 Get It

BACKGROUND: Current clinical guidelines emphasize the significance of rhythm control with catheter ablation but lack guidance on the timing of atrial fibrillation (AF) ablation relative to the diagnosis time. We aim to investigate the latest evidence on the impact of diagnosis to ablation time (DAT) on clinical outcomes after AF ablation. METHODS: We searched PubMed, Web of Science, Scopus, Embase, and Cochrane Central Register of Controlled Trials through August 2024. Pairwise, prognostic, and reconstructed time-to-event data meta-analyses were conducted using R V. 4.3.1. Our primary end point was time to first AF recurrence, with secondary end points of all-cause mortality, tamponade, stroke, and heart failure. RESULTS: Our cohort included 23 studies with 43 711 patients. Shorter DAT was significantly associated with reduced AF recurrence across both paroxysmal and persistent AF subgroups ( P <0.01). There was a significant decrease in benefit for paroxysmal AF over time and a slight decrease in benefit for persistent AF over time. However, the benefit remained significant in both over time. DAT per year was significantly associated with a 10% increased risk of AF recurrence. Reconstructed Kaplan-Meier analysis showed that DAT >1 year was significantly associated with a 70% increased risk of AF recurrence in paroxysmal AF and 30% in persistent AF. DAT ≤1 year was significantly associated with decreased all-cause mortality ( P <0.01) and showed a trend toward an association with a lower incidence of stroke ( P =0.08). However, there was no significant difference in heart failure between DAT ≤1 year and DAT >1 year. CONCLUSIONS: Early ablation is more beneficial in paroxysmal AF, with a notable decrease in benefit over time, while in persistent AF, the benefit remains significant but slightly decreases over time. Shorter DAT was significantly associated with decreased all-cause mortality and showed a trend toward an association with a lower incidence of stroke. REGISTRATION: URL: https://www.crd.york.ac.uk/prospero/display_record.php? ; Unique identifier: CRD42024525542.